Logo

Galapagos & Servier's GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis

Share this
Galapagos & Servier's GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis

Galapagos & Servier's GLPG1972/S201086 Fails to Meet its Primary Endpoint in P-II ROCCELLA Study for Knee Osteoarthritis

Shots:

  • The P-II ROCCELLA is a dose-ranging trial involves assessing GLPG1972/S201086 (PO- qd) in three different doses vs PBO in 932 patients with knee OA for 52wks. across 12 countries including EU- Asia- North and South America. Galapagos is responsible for ROCCELLA in the US- where 326 patients were recruited while Servier will be solely responsible for trial in 11 countries where 606 patients were recruited
  • The trial failed to meet its 1EPs as the change from baseline to 52 in cartilage thickness in mm (SD) is {-0.068 (0.20)- -0.097 (0.27) & -0.085 (0.22)} vs -0.116 (0.27) for the low- medium & high dose respectively
  • No difference in 2EPS including clinical outcomes- the therapy was generally well-tolerated by patients in the P-II study

 ­ Ref: Globe Newswire | Image: Servier

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions